North America

Merck buys ArQuele for $2.7 billion

Merck said Monday that it iwll, through a subsidiary, initiate a tender offer to acquire all outstanding shares of ArQule for nearly $2.7 billion, or for $20 per share in cash.

Posted in news, North America | Tagged | Leave a comment

FDA to fast track Equillium’s itolizumab for lupus nephritis

Equillium got U.S. FDA’s Fast Track designation for itolizumab for the treatment of lupus nephritis, after startign the phase 1 study of itolizumab in patients with lupus and lupus nephritis in September 2019.

Posted in news, North America | Tagged , , | Leave a comment

Inceptua, Onconova Therapeutics in pre-approval access collaboration

Inceptua Medicines Access, a business unit of the Inceptua Group, has announced the collaboration with Onconova Therapeutics to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.

Posted in news, North America | Tagged , | Leave a comment

Actinium’s phase 3 trial dosimetry results support low dose iomab-B for targeted lymphodepletion prior to adoptive cell therapy

Actinium Pharmaceuticals is advancing the development of low dose Iodine-131 apamistamab, a CD45 targeting antibody radiation-conjugate (ARC), as an alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens like fludarabine/cyclophosphamide (Flu/Cy), which have been implicated in CAR-T toxicities including cytokine release syndrome (CRS) and neurotoxicity.

Posted in news, North America | Tagged | Leave a comment

Novartis’ clinical trial of inhaled dual combination QMF149 for patients with asthma, meets primary endpoint

Novartis Phase III Palladium clinical trial has met the primary endpoing, as it showed that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate (IND/MF) in development, was superior to mometasone furoate (MF) at medium and high doses in improving lung function.

Posted in news, North America | Tagged , | Leave a comment

Lilly adds new leadership to new organization Loxo Oncology

Eli Lilly said Thursday it will work with new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019.

Posted in Europe, news, North America | Tagged , | Leave a comment

Novartis to work on transformational treatment options

Today Novartis holds an investor event in London to provide a comprehensive overview of the its progress in advancing its industry-leading R&D pipeline.

Posted in news, North America | Tagged | Leave a comment

ValiRx gets a US patent for its anticancer therapeutic compound, sees it as validation of its potential anti-cancer impact

ValiRx got patent from the US Patent and Trademark Office for modulators Of the SRC-kinase activity for preventing or treating

Posted in news, North America | Tagged , , | Leave a comment

HIkma responds to FDA about GSK’s Advair Diskus

Hikma has submitted to the US Food and Drug Administration (FDA) its response to deficiencies in its abbreviated new drug application (ANDA) for a generic version of GlaxoSmithKline’s Advair Diskus® (fluticasone propionate and salmeterol inhalation powder).

Posted in Middle East and North Africa, news, North America | Tagged , | Leave a comment

Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today that it currently expects there will be no further extension

Posted in news, North America | Leave a comment